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Abstract: Hepatoblastoma (HB) is the most common malignant liver tumor that occurs during
childhood. The prognosis of children with HB is favorable when a complete surgical resection of the
tumor is possible, but for high-risk patients, the prognosis is much worse. New anti-HB strategies
must be urgently developed. The undecapeptide substance P (SP) after binding to the neurokinin-1
receptor (NK-1R), regulates cancer cell proliferation, exerts an antiapoptotic effect, induces cell
migration for invasion/metastasis, and triggers endothelial cell proliferation for neoangiogenesis.
HB samples and cell lines overexpress NK-1R (the truncated form) and SP elicits HB cell proliferation.
One of these strategies could be the use of non-peptide NK-1R antagonists. These antagonists
exert, in a concentration-dependent manner, an antiproliferative action against HB cells (inhibit cell
proliferation and induce the death of HB cells by apoptosis). NK-1R antagonists exerted a dual effect
in HB: Decreased both tumor volume and angiogenic activity. Thus, the SP/NK-1R system is an
important target in the HB treatment and NK-1R antagonists could act as specific drugs against HB
cells. In this review, we update and discuss the use of NK-1R antagonists in the treatment of HB.
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1. Introduction
Hepatoblastoma (HB) is the most frequent primary malignant liver tumor in children (generally
between six months to three years). In western countries, the annual incidence is 1.2 cases per 1 million
children [1]. The disease stage is the current key to the patient outcome. The prognosis of children
with HB is favorable in the cases of lower risk, having a five-year event-free survival rate of 80%;
however, in the group of high risk, or after relapse, survival decreases by 30–40% [2]. Unfortunately,
for 25% of the patients with metastasis, overall survival remains extremely poor [3]. Therefore, it is
urgent to identify new therapeutic targets and to develop new clinical strategies to improve the HB
patient outcome.
It is well known that some peptides and their receptors are involved in cancer. This is the case of
the substance P (SP)/neurokinin-1 receptor (NK-1R) system (Figure 1), since SP, via the NK-1R, acts as
a universal mitogen in human cancer cells (including HB) (Table 1) [4–6]. SP also exerts an antiapoptotic
effect in tumor cells, induces the migration of these cells and elicits neovascularization [4]. Human
tumor cells (including HB) overexpress NK-1R, this receptor being involved in the viability of these
cells; this means that NK-1R can be considered a new tumor marker [4–6]. This is crucial, since it is also
well known that NK-1R antagonists (currently, there are more than 300 compounds: Such as the drug
aprepitant, L-732,138, L-733,060) exert multiple antitumor activities (antiproliferative, apoptotic effect,
antimigration, antiangiogenesis) [7]. Due to the large amount of data confirming that the SP/NK-1R
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system is involved in cancer, here we review the involvement of this system in the HB development
and we also suggest a new therapeutic strategy against HB: The use of NK-1R antagonists.
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Figure 1. The substance P/neurokinin-1 receptor (SP/NK-1R) system regulates several cell signaling 
pathways involved in cancer progression. These pathways are the following: (a) Antiapoptotic 
signaling pathway (PI3K/Akt/mTOR); (b) cell proliferation signaling pathway (PKC, MAPKs, ERK); 
(c) cell migration signaling pathway (Rho-ROCK-pMLC); (d) Wnt signaling pathway (β-catenin, c-
myc, cyclin D1); (e) AC-cAMP-PKA phosphorylation signaling pathway, and (f) the Warburg effect 
(GSK-3β). APC: Adenomatous polyposis coli; Dvl: Dishevelled; Fzd: Frizzled receptor; PCP: Planar 
cell polarity pathway; PDK-1: Phosphoinositide-dependent kinase-1; pMLC: Myosin light-chain 
kinase; TCF/LEF: Transcription factor/lymphoid enhancer-binding factor. 
Table 1. The SP/NK-1R system in human HB cell lines (HepT1; HepG2; HuH6). 
Heading title Heading title 
NK-1R 
Express mRNA for the NK-1R 
Expression of the TAC1R gene is increased 
Express full and truncated isoforms of the NK-1R. The HB cells express essentially the truncated 
form. Expression of the full form is higher in non-tumor cells 
SP A universal mitogen (at nanomolar concentration) of tumor cells, including HB cells 
Non-peptide NK-1R 
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Antiproliferative action in a concentration-dependent manner: The higher the concentration, the 
greater the antitumor activity 
Induce cell death by apoptosis, cleavage of caspase-3and proteolysis of poly (ADP-ribose) 
polymerase 
Aprepitant (IC50) for HepT1 (31.1 µM), HuH6 (33.18 µM), HepG2 (38.61 µM) 
L-732,138 (IC50) for HepT1 (42 µM), HuH6 (41 µM), HepG2 (110 µM) 
L-733,060 (IC50) for HepT1 (15 µM), HuH6 (14 µM), HepG2 (17 µM) 
Co-administration of aprepitant and cytostatics exerts a synergistic antitumor effect 
Pretreatment of non-tumor cells (human embryonic kidney (HEK)-293) with aprepitant, 
protected these cells from cytostatic toxicity 
Figure 1. The substance P/neurokinin-1 receptor (SP/NK-1R) system regulates several cell signaling
pathways involved in cancer progression. These pathways are the following: (a) Antiapoptotic
signaling pathway (PI3K/Akt/mTOR); (b) cell proliferation signaling pathway (PKC, MAPKs, ERK);
(c) cell migration signaling pathway (Rho-ROCK-pMLC); (d) Wnt signaling pathway (β-catenin, c-myc,
cyclin D1); (e) AC-cAMP-PK phosphorylation signaling pathway, and (f) the Warburg effect (GSK-3β).
APC: Adenomatous polyposis coli; Dvl: Dishevelled; Fzd: Frizzled receptor; PCP: Planar cell pol rity
pathway; PDK-1: P osphoinositide-de endent kinas -1; pMLC: Myosin light-chain k ase; TCF/LEF:
Transcription factor/lymphoid e h ncer-binding factor.
Table 1. The SP/NK-1R system in human HB cell lines (HepT1; HepG2; HuH6).
NK-1R
Express mRNA for the NK-1R
Expression of the TAC1R gene is increased
Express full an ncated is forms of the NK-1R. Th HB c lls express essentially the
truncated form. Expr ssion of the full form is high r in non-tumor cells
SP A universal mitogen (at nanomolar concentration) of tumor cells, including HB cells
Non-peptide
NK-1R antagonists
Antiprolifer tive action in a concentration-dependent manner: The higher the
concentration, t e greater the antitumor activity
Induce cell death by apoptosis, cleavage of caspase-3and proteolysis of poly
(ADP-ribose) polymerase
Aprepitant (IC50) for HepT1 (31.1 µM), HuH6 (33.18 µM), HepG2 (38.61 µM)
L-732,138 (IC50) for HepT1 (42 µM), HuH6 (41 µM), HepG2 (110 µM)
L-733,060 (IC50) for HepT1 (15 µM), HuH6 (14 µM), HepG2 (17 µM)
Co-administration of aprepitant and cytostatics exerts a synergistic antitumor effect
Pretreatment of non-tumor cells (human embryonic kidney (HEK)-293) with aprepitant,
protected these cells from cytostatic toxicity
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2. The SP/NK-1R System
The undecapeptide SP, hemokinin-1, neurokinin A and B belong to the tachykinin peptide family
and, via NK-1R, NK-2R and NK-3R, many physiological actions are exerted: NK-1R shows a preferential
affinity for SP/hemokinin-1, NK-2R for neurokinin A and NK-3R for neurokinin B [7]. The NK-1R protein
is encoded by the TACR1 gene (located in chromosome 2); the receptor belongs to the 1 (rhodopsin-like)
G protein-coupled receptors family (also known as 7TM receptors, seven-transmembrane domain
receptors or serpentine receptors) and can be coupled to several groups of G proteins: Gαi, Gαs and
Gαq (Figure 1) [8,9]. The activation of a determined G protein is regulated by the conformation of the
receptor as well as the type of ligand [10,11]. The G proteins differ in their signaling pathway/effectors
that they activate (Figure 1) [12]. Thus, the coupling of NK-1R with the Gαi protein inhibits activity
of the adenylate cyclase and decreases the level of cyclic adenosine monophosphate [13,14], whereas
coupling of NK-1R with the Gαs protein activates the adenylate cyclase, the production of cyclic
adenosine monophosphate, the activation of the protein kinase A and the phosphorylation of specific
substrates (Figure 1) [15]. The coupling of NK-1R with the Gαq protein promotes the activation of
phospholipase Cβ, an increase in the phosphatidylinositol-3 kinase, the release of diacylglycerol and
an increase in the intracellular level of Ca++ (Figure 1) [16]. Through these pathways, the transcription
of specific genes is regulated.
Seven-transmembrane-helix receptors share the same structural unit (Figure 1): An amino-terminal
extracellular domain (responsible for the specificity of the receptor), a carboxy-terminal cytoplasmic
domain (the carboxy-terminal conserved domain of tachykinins (Phe-X-Gly-Leu-Met-NH2) interacts
with the receptor), and three extracellular (EL1, EL2, EL3) and intracellular (C1, C2, C3) loops
flanked by seven intermembrane domains [17]. The second and third loops are involved in the
binding of the SP agonists to residues 178–183 (Val-Val-Cys-Met-Ile-Glu) located in the middle of
the second extracellular loop (EL2): A covalent link occurs between SP and the methyl group of
a methionine residue (Met-181) [18]. The third cytoplasmic loop (C3) is responsible for the binding
to protein G. The C-terminus contains serine/threonine residues, which once phosphorylated, cause
desensitisation/internalization of the receptor, the latter being recycled to the plasma membrane [19].
Internalization of the NK-1R depends on the concentration of SP: Low concentration, the receptor is
internalized and quickly recycled to the plasma membrane but, at high concentration, the mechanism
is slower (endocytosis into endosomes) [20]. Moreover, it has been reported that the loss of certain
C-terminal serine/threonine residues is important for the G protein-coupled receptor kinase interaction
and β-arrestin recruitment for subsequent receptor internalization (Figure 1) [21].
Two isoforms of NK-1R have been reported: The truncated (tr-NK-1R) and the full-length
(fl-NK-1R) [6,22,23]. The first contains 311 amino acids (at the C-terminus, the last 96 amino acids are
lost: A premature stop codon does not allow that intron between exons 4/5 to be removed) [12] and
the second one has 407 amino acids. The loss of the last 96 amino acids has been related to a loss of
internalization [24]. The tr-NK-1R is able to prolong the responses after the binding of the ligands
(due to the absence of a rapid desensitization) and, due to the different structure of both isoforms,
it seems that they have a different functional significance, differing in cell signaling capability [25].
The tr-NK-1R promotes a rapid and sustained Ca++ response [24].
The presence of NK-1R has been reported in many human cancer cell lines/tissue samples and,
after application of a knockdown gene-silencing method, it has been demonstrated that NK-1R plays
a crucial role in the viability of tumor cells [5,26]. It seems that the degree of malignancy of a tumor
correlates with the number of NK-1Rs: Greater number, higher malignancy [27] and that a poorer
prognosis correlates with NK-1R overexpression [4,28]. Moreover, it is known that in malignant tissues
the expression of NK-1R mRNA increased, but not in the benign tissues [27,29].
SP and the NK-1R have been observed in HB samples and the NK-1R in human HB HepT1, HepG2
and HuH6 cell lines; these three cell lines expressed mRNA for the NK-1R, and it is known that the
expression of the TAC1R gene was increased approximately by 7.5–30 fold in HB cell lines compared to
fibroblasts (Tables 1 and 2) [6]. It is important to note that the above human HB cell lines expressed
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both isoforms of the NK-1R (fl-NK-1R and tr-NK-1R), but human HB HuH6, HepT1 and HepG2 cell
lines expressed essentially tr-NK-1R and, in comparison to these cell lines, the fl-NK-1R expression was
highest in the human embryonic kidney (HEK)-293 cells and human fibroblasts (Table 1) [6]. By contrast,
the latter two cells showed a reduced number of the tr-NK-1R form [6]. It is important to note that
the HEK-293 cells and fibroblasts, when studying cell survival, showed the strongest resistance to
aprepitant [12]. This suggests that the action of the NK-1R antagonists is related to the differential
expression of the NK-1R [12]. Moreover, it seems that the tr-NK-1R form remains up-regulated and
activated continuously (as indicated above, it seems that this isoform is not internalized) and for this
reason the tr-NK-1R isoform has been linked to cancer progression [25]. It has also been reported that
the expression of the full-length isoform was inversely associated with proliferation, invasiveness and
metastasis and that the overexpression of the tr-NK-1R isoform promotes a malignant transformation
of cells, tumor progression and metastasis [30]. It is also important to note that in patients with cancer,
compared to healthy subjects, the level of SP in the serum was higher [31] and that the level of the
undecapeptide was > 7-fold in cultured cancer cells than in cultured normal epithelial cells [29]. Finally,
in 47 children with HB, it was reported that the tr-TACR1 isoform was expressed ubiquitously among
the different subsets of HB (Table 2). This finding is also important since the NK-1R may serve as
a therapeutic target in HB patients, independent of the clinical stage/tumor biology [32]. Moreover,
the tr-TACR1 was more expressed in children with HB than in non-tumor controls, but the expression
of the fl-TACR1 showed no difference between the two groups [12]. Thus, it seems that the tr-NK-1R
but not the fl-NK-1R is associated with cancer [12].
Table 2. The SP/NK-1R system in the human HB sample and tumor.
Items HB Sample HB Tumor
SP/NK-1R system Expression of bothSP and NK-1R
Truncated-TACR1 isoform is expressed ubiquitously among the
different subsets of children with HB
Non-peptide
NK-1R antagonists
In experimental animals: Dual effect of aprepitant (80 mg/kg/day
for 24 days). The antagonist decreased the tumor volume (tumor
cells die by apoptosis) and the angiogenic activity (decrease of
the vascularized area, but not the microvascular density).
Aprepitant lowered the tumor-specific alpha-fetoprotein serum
level and decreased the number of Ki-67 positive cells
3. Involvement of the SP/NK-1R System in HB Progression
SP, via the NK-1R, acts as a universal mitogen in normal and tumor cells (e.g., HB, neuroblastoma,
melanoma, retinoblastoma, glioma, osteosarcoma) (Table 1) [5,6,33]. In tumor cells, SP promotes c-myc
mRNA and protein synthesis, c-myc being crucial for the progression through the S phase to G2/M in
the cell cycle (Figure 1) [34,35]. It has been reported that c-myc is necessary to sustain a rapid tumor
growth [36]. SP, via NK-1R, promotes the formation of an activated epidermal growth factor receptor
(EGFR) complex, induces the transactivation of EGFR, activates the mitogen-activated protein kinase
(MAPK) pathway, induces the activation of extracellular signal-regulated kinase (ERK)2, and the
synthesis of DNA occurs (Figure 1) [37]. According to these data, it seems that the signaling pathways
between the NK-1R and growth factors (e.g., EGFR) converge at an upstream point, favouring the
pathways by which SP regulates cell proliferation [37]. It is known that c-Src interacts with EGFR
inducing its phosphorylation and that the increased activity/overexpression of c-Src is related to
cancer progression (Figure 1), since its interaction with EGFR/Her2 enhances mitogenic signaling
pathways [38].
SP is synthesized/secreted by non-tumor and tumor cells; it can be released from the tumor
mass into blood vessels and/or released from nerve terminals (this is important since SP regulates
tumor growth and this means that an interaction between cancer cells and the nervous system
occurs) [4,7]. Since several years ago, the involvement of the SP/NK-1R system in cancer (e.g.,
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melanoma, retinoblastoma, glioma) [4,5,7] is known; however, there are few original data on the
involvement of this system in HB (Tables 1 and 2). In fact, only one review [12] and two research
papers [6,32] have been currently published on the field. Thus, there are many scientific questions to be
solved in the future on the involvement of the SP/NK-1R system in HB (Table 3). SP has been observed
in the HB samples; the undecapeptide (at nanomolar concentration) promotes the proliferation of the
HB cell lines (HepT1, HepG2, HuH6) and NK-1R antagonists (e.g., aprepitant, L-732,138, L-733,060)
counteract the mitogenic action exerted by SP (Tables 1 and 2) [6]. SP, via the NK-1R, promotes
the DNA synthesis in cancer cells, activating members of the MAPK family (p38MAPK, ERK1/2)
(Figure 1) [34]. Then, ERK1/2 is translocated into the nucleus, promoting cell proliferation and exerting
an antiapoptotic effect [21].
Table 3. Key points in future HB research.
NK-1R
NK-1R: A new HB tumor marker
NK-1R: Therapeutic target in HB patients, independent of the clinical stage/tumor biology
NK-1R: Involved in the viability of HB cells?
The tr-NK-1R, but not the fl-NK-1R, is associated with cancer?
The response of the NK-1R antagonists depends on the differential expression of the
receptor (truncated/full)?
tr-NK-1R: Responsible for a constitutive growth stimulus in the HB cells?
Overexpression of the tr-NK-1R: Correlates with poorer prognosis and advance HB stages?
tr-NK-1R: Not internalized in the HB cells? Involved in the malignant transformation of
the HB cells?
SP
Level of SP in the serum of HB patients
SP activates GSK-3β in the HB cells (Warburg effect)?
SP is released from the HB cells to promote neovascularization?
SP triggers the migration of HB cells?
3.1. PI3K/Akt/mTOR Signaling Pathway
This pathway is involved in cell proliferation and survival and it is activated via the receptor
tyrosine kinase, which can be activated by cytokines or the epidermal growth factor (Figure 1) [12].
The activation of this pathway (crucial to drug resistance) promotes the activation, through
phosphorylation, of many intracellular proteins. In experimental animals, it has been reported
that the inhibition of mTOR affects the β-catenin/Yes-associated protein 1-induced HB development
and growth [39]. The antiapoptotic effect of SP has been demonstrated in many cells (e.g., macrophages,
neutrophils, thymocytes) and it is known that SP increases the phosphorylation and activity (via PI3K)
of Akt (protein kinase B) (Figure 1); this activation suppresses apoptosis [11,21,40,41]. In macrophages,
SP activates the PI3K/Akt/mTOR/S6kinase pathway [42], the activation of the PI3K/Akt/mTOR pathway
being crucial for the HB survival. Most tumors express p-GSK-3β, p-Akt and p-mTOR and some of
them show a significant expression of cyclin D1, p21, and p27.
It has been demonstrated that the inhibition of PI3K diminished the HB cell growth, this being
accompanied by a reduced phosphorylation of both GSK-3β and Akt (Figure 1). The inhibition of
PI3K increases the HB apoptosis and decreases the HB cellular proliferation, this being linked to
increased p27 and reduced cyclin D1 levels [43]. In human HB HepT1, HepG2 and HuH6 cell lines,
it has been reported that the Akt signaling pathway is a target of aprepitant [44]. After blockage
of the NK-1R with aprepitant, both phosphorylation sites (S473, T308) of Akt and mTOR (S2448)
become increasingly phosphorylated (that is, an activation of upstream Akt/mTOR signaling occurs),
whereas downstream components of Akt/mTOR (4E-BP1/2, p70S6K) are downregulated [12,44]. In the
nucleus of the HB cells and after administration of aprepitant, the presence of phosphor-Akt (S473) and
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phosphor-mTOR (S2448) has been reported [12]. In the nucleus, Akt can phosphorylate intracellular
components promoting DNA repair/cell survival [45]. It has been suggested that the activation of Akt
could be related to a cellular mechanism that avoids cell death and contributes to drug resistance,
attenuating the antitumor efficacy of aprepitant [12,46,47]. This could explain why, in experimental
animals, although aprepitant significantly reduced the volume of the HB tumor, a slight increase of the
volume was observed after twenty days of treatment [6,12]. In summary, the data suggest that the
PI3K/Akt/mTOR signaling pathway (Figure 1) plays a crucial role in the HB growth inhibition exerted
by NK-1R antagonists.
3.2. Wnt Signaling Pathway
This pathway plays an important role in survival, differentiation and cell proliferation
(Figure 1) [12]. In most HB, missense mutations/exon-3 deletions in gene coding for β-catenin
(a downstream effector of the Wnt signaling pathway) have been reported and HB has been associated
with an aberrant activation of the β-catenin pathway (Figure 1) [3,36]. The Wnt pathway is activated
via inhibition of the β-catenin degradation; thus, the level of β-catenin is increased and then the
protein is translocated into the nucleus promoting cell proliferation (Figure 1) [12]. Wnt3a is reported
to activate the ERK pathway through Ras, Raf and mitogen-activated protein kinase kinase (MEK);
that it is involved in cellular proliferation, and that it activates p38MAPK which is crucial for the
accumulation of β-catenin (this accumulation promotes tumorigenesis) (Figure 1) [48]. Wnt signaling
has been reported as corroborating an active canonical Wnt signaling and it is known that SP activates
the Wnt signal transduction pathway and enhances the proliferation of stem cells (Figure 1) [49,50].
Wnt signaling is involved in the SP inhibition of apoptosis. SP exerts a protective effect, reduces
the apoptotic rate, produces nuclear condensation and the activation of caspase-3 and caspase-9.
The inhibition of Wnt signaling or NK-1R antagonists blocked this effect. SP promotes the mRNA
and protein expression of Wnt signaling molecules such as β-catenin, GSK-3β, c-myc and cyclin D1
(Figure 1) [51].
In human HB HepT1, HepG2 and HuH6 cell lines treated with aprepitant, it has been demonstrated
that the Wnt and Akt signaling pathways are the targets of NK-1R antagonists [44]. Aprepitant inhibited
the canonical Wnt pathway (evidenced by the decrease of β-catenin and the downregulation of the Wnt
target genes AXIN2 and LGR5) (Figure 1); it decreased the phosphorylation of 4E-BP1/2 and p70S6K,
and it decreased the growth of the HB cells [44]. Aprepitant is also involved in the downregulation of
FOXM1 (a protein involved in the translocation of β-catenin into the nucleus) [12,52]. It seems that the
inhibition of the Wnt pathway is strengthened by the FOXM1-β-catenin complex disruption, enhancing
growth arrest and apoptotic mechanisms [44]. It is also important to note that aprepitant decreased
stemness property/canonical Wnt signaling in Wnt-dependent cancer stem cells [12]. This is extremely
important because it seems that cancer stem cells are involved in tumor relapse/resistance [53].
4. NK-1R Antagonists as Anti-HB Drugs: Mechanisms of Action and Therapeutic Properties
There are peptide and non-peptide NK-1R antagonists. Peptide NK-1R antagonists are degraded
by peptidases, they are not brain-penetrant and some of them exert toxic effects, but non-peptide
NK-1R antagonists (e.g., rolapitant (Varubi), aprepitant (L-754,030, MK-869, Emend), GR-205,171
(Vofopitant), CP-96,345, WIN-51,708, L-733,060, L-732,138) are not degraded by peptidases and they
can cross the blood-brain barrier [7]. Thus, non-peptide NK-1R antagonists show more therapeutic
advantages than peptide NK-1R antagonists which are toxic and unstable [54]. Only three NK-1R
antagonists (non-peptide) have been approved for humans: Aprepitant, its pro-drug (fosaprepitant,
MK-0517, L-758,298, Ivemend) and rolapitant (Varubi). SP binds to the extracellular loops of the
receptor, but non-peptide NK-1R antagonists (lipid soluble) bind more deeply [55]. It is important
to note that the therapeutic action of non-peptide NK-1R antagonists, after binding to the fl-NK-1R
or the tr-NK-1R isoforms, is similar because such action is not associated with the intracellular
C-terminus. Non-peptide NK-1R antagonists (e.g., aprepitant (morpholine derivative), L-733,060
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(benzyletherpiperidine), L-732,138 (tryptophan-based)) are broad spectrum antitumor compounds
that exert an antitumor action against many human cancer cells (e.g., HB, neuroblastoma, glioma,
melanoma, retinoblastoma, acute lymphoblastic leukaemia B and T cells, gastric, colon, breast, larynx
and pancreatic carcinoma) (Table 1) [4,6]. The antitumor action exerted by these antagonists is in
a concentration-dependent manner: The higher the concentration, the greater the antitumor activity
(Table 1) [4,6].
4.1. Antiproliferative Effect
Human HB cells overexpress the NK-1R (truncated form) and NK-1R antagonists (L-733,060,
L-732,138, aprepitant) after binding to the NK-1R, exerting an antiproliferative action against the HB
cells lines (HepT1, HuH6, HepG2) (Table 1) [6]. Thus, the IC50 of aprepitant for HB HepT1, HuH6
and HepG2 cells were 31.1 µM, 33.18 µM, and 38.61 µM respectively; 42 µM, 41 µM, and 110 µM
(for L-732.138), and 15 µM, 14 µM, and 17 µM (for L-733,060) (Table 1) [6]. It seems that this effect is
due to the blockade of the MAPK cascade (including p38MAPK and ERK1/2 signaling). It is known
that SP, through the G-protein βγ subunit, which recruits components of the Ras-dependent cascade
(e.g., SHC, GRB2, Src), leads to the activation of Raf-1 and MAPK 1, a specific activator of ERK1/2
(Figure 1) [56]. Thus, NK-1R antagonists could counteract this pathway. In a HuH6 xenograft mouse
model (80 mg/kg/day aprepitant for 24 days), reduction of tumor growth (reduced tumor volume and
weight) was reported along with a lowered tumor-specific alpha-fetoprotein (a marker of HB) serum
level and a decreased number of Ki-67 positive cells (Table 2) [6]. In this model, NK-1R antagonists
induced a dual effect: Decreased the volume of the tumor (tumor cells die by apoptosis, see below)
and exerted an antiangiogenic effect (Table 2) [6].
4.2. Apoptotic Effect
NK-1R antagonists (L-733,060, L-732,138, aprepitant) promoted apoptosis in human HB HepT1,
HuH6 and HepG2 cell lines (Table 1) [6]. Moreover, in HB, NK-1R antagonists increased the percentage
of cells with subdiploid DNA features of apoptotic death; caused the cleavage of caspase-3 and the
proteolysis of poly (ADP-ribose) polymerase (Table 1) [6]. This same NK-1R antagonist is known to
promote apoptosis in many other tumor cells [4] and the blockade of this receptor by L-733,060 caused
the cleavage of caspase-3 and the proteolysis of poly (ADP-ribose) polymerase, increased apoptosis
and inhibited the basal kinase activity of Akt [57]. In the Akt phosphorylation mediated by the NK-1R,
the full involvement of PI3K/the non-receptor tyrosine kinase Src was reported as well as the partial
involvement of EGFR and the non-involvement of MAPK/ERK (Figure 1) [57]. It is known that the
expression of the NK-1R is pivotal for the survival of cancer cells. By eliminating the expression of
this receptor in cancer cells, due to apoptotic mechanisms, a decrease in the number of these cells has
been reported and it is also known that in tumor cells the application of the siRNA TAC1R method
decreased the levels of p-EGFR, p-Akt and p-ERK (Figure 1) [5,26,58].
4.3. Anti-Warburg Effect
In order to obtain energy, cancer cells show a high rate of glycolysis (200 times higher than those
of their normal tissues of origin) followed by lactic acid fermentation (Warburg effect) [4,59]. In cancer
cells, SP (via the NK-1R) increases the concentration of intracellular Ca++ (Figure 1), induces the
breakdown of glycogen and then, due to the glucose obtained, these cells increase their metabolism;
however, NK-1R antagonists block such a breakdown and cancer cells die from starvation [60]. The
glycogen synthase is involved in glycogenesis, whereas glycogen synthase kinase-3 (GSK-3β) (Figure 1)
inactivates the glycogen synthase and produces glucose. It has been reported that GSK-3β is linked to
poor prognostic/cancer progression and that the inhibition of GSK-3β suppresses tumorigenesis by
attenuating cell proliferation, while increasing apoptosis and restraining cell motility [61,62]. Inhibitors
of GSK-3β reduce glucose output and increase the synthesis of glycogen from L-glucose, counteracting
the Warbur effect and it is also known that SP activates GSK-3β and that NK-1R antagonists inhibit
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GSK-3β activity [57]. The previous data suggest that NK-1R antagonists could counteract the Warburg
effect by inhibiting the GSK-3β activity in HB cells. This must be confirmed in future studies (Table 3).
4.4. Antiangiogenic Effect
Neoangiogenesis is crucial in advanced stages of the inflammatory process and in tumor growth
development, this being associated with an increased innervation of the tissue and an overexpression
of the NK-1R [4,28]. The increased level of SP found in chronic inflammatory conditions plays an
important role in the development of new vessels [63]. Infiltrating immune cells express SP and NK-1R
and the peptide exerts a pro-inflammatory action [12,64]. It is well known that the blood vessels
located in the tumor/peritumoral region express both SP and NK-1R [28]. The SP/NK-1R system is
involved in the proliferation of endothelial cells, followed by the formation of blood vessels (increasing
vascularization) and by an increase in blood flow and hence neovascularization is crucial for the growth
of the tumor mass [65]. However, NK-1R antagonists block such proliferation [4,66].
It has been reported that SP promotes the release of IL-1, IL-6, IL-10, IL-12 and TNFα from
inflammatory cells; that SP controls both secretion and gene expression of the vascular endothelial
growth factor (VEGF, a pro-angiogenic factor involved in many inflammatory diseases); that this
secretion increased when SP and IL-33 were co-administered, and that NK-1R antagonists inhibited the
previously mentioned effects exerted by SP [67]. Moreover, it is known that calcium-dependent protein
kinase C isoforms, ERK, c-jun N-terminal kinases (JNK) and MAPKs are involved in the production
of the VEGF regulated by SP [67]. SP is expressed in human HB tumors [6]. This suggests that via
a paracrine action, the SP released from the HB cells could favor the vascularization of the HB tumor by
stimulating, via the NK-1R expressed in endothelial cells, the proliferation of these cells. This paracrine
action must be confirmed in future studies.
In a human pancreatic xenograft model, it has been demonstrated that a peptide NK-1R antagonist
blocked the growth of the tumor by antiproliferative and antiangiogenic mechanisms [68]. This was
also observed in a HB xenograft nude mouse model [6]. Thus, aprepitant blocked the HB growth by
inhibiting both HB cell proliferation and angiogenesis (Table 2): A decrease of the vascularized area
was observed, but not of the microvascular density [6]. The finding confirms that NK-1R antagonists
counteract angiogenesis in HB.
4.5. Antimetastatic Effect
In advanced stages of HB, invasion and metastasis occur and unfortunately for 25% of the patients
with HB metastasis, the overall survival remains poor [3]. Membrane blebbing plays an important role
in cell movement/spreading and in tumor cell infiltration/invasion [69]. It is known that SP promotes
the migration of tumor cells (SP favors the formation of membrane blebbing) for invasion/metastasis;
that SP increased the expression of VEGF-C and matrix metalloproteinase favoring tumor metastasis;
that NK-1R antagonists inhibit such an increase [70,71], and that these antagonists block the changes in
the cell shape (including blebbing) induced by SP (in the latter mechanisms Rho-associated protein
kinase (ROCK) was involved) (Figure 1) [72]. In tumor cells (but not in non-tumor cells), SP induced the
phosphorylation of p21-activated kinase and augmented the phosphorylation of the myosin regulatory
light chain kinase [73]. Moreover, the loss of the EGFR-ASAP-1 signaling has been reported to be an
important characteristic of invasive/undifferentiated HB [74].
Since the HB cells express both SP and the NK-1R [6], it is possible that the peptide could trigger
the migration of the HB cells for invasion/metastasis and that it could be blocked by NK-1R antagonists.
This must be confirmed in the future (Table 3).
4.6. Combination Therapy Using NK-1R Antagonists
In HB patients, the high-risk group is characterized by a marked chemoresistance and poor
outcome [75]. Multidrug resistance often occurs after four cycles of chemotherapy [12]. In clinical
practice, the main goal of the combination therapy is to increase the therapeutic effects (additive
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or synergistic) of a drug. In HB, the adjuvant chemotherapy regimens include cisplatin (induces
ototoxicity/nephrotoxicity) [76], doxorubicin (DOX) (induces cardiotoxicity) [77] and microtubule
destabilizing agent (MDAs, e.g., vinorelbine, vincristine) treatments. In human HB HepT1, HuH6
and HepG2 cell lines, it has been demonstrated that aprepitant and cytostatics showed a synergistic
effect (Table 1) [6]. In HepT1 cells, a synergistic effect for DOX/aprepitant was found, but this effect
was not observed in the case of cisplatin/aprepitant [6]. In HepG2, a synergistic effect was found for
aprepitant/DOX or cisplatin [6]. Even the effects of aprepitant/DOX (low-dose) were significantly
higher when compared to the treatment with single compounds. In HuH6, similar results were
obtained [6]. These data suggest that in HB patients aprepitant, in combination therapy with the
above-mentioned drugs, could exert a synergistic therapeutic effect. Moreover, it has been demonstrated
that pre-treatment of non-tumor HEK-293 cells with a NK-1R antagonist (before exposure to cytostatics),
protected the HEK-293 cells from cytostatic toxicity (Table 1) [33].
Treatment with DOX is known to elicit cardiotoxicity [77] and that the SP/NK-1R system mediates
this DOX cardiotoxicity. In tumor cells, the treatment with aprepitant increased cell death by
apoptosis, reactive oxygen species synthesis and DOX-induced reduction of cell viability, whereas in
cardiomyocytes treatment with the same drug decreased apoptosis, reactive oxygen species synthesis
and DOX-induced reduction of cell viability [78].
NK-1R antagonists and MDAs exert a synergic effect. MDAs trigger apoptotic signaling through
JNK, and the modulation of the MAPK pathway can inhibit or enhance the apoptosis induced by MDAs.
It seems that NK-1R antagonists sensitizes tumor cells to the MDA-mediated inhibition of cell viability
by reducing the anti-apoptotic NK-1R signaling, thus enhancing the cell death induced by MDAs [79].
This combination is synergistic for the growth inhibition of cancer cells expressing the NK-1R, but not
for non-cancer cells. Moreover, the combination therapy of NK-1R antagonists/cytostatics decreases the
toxicity/side-effects of chemotherapy and it is less toxic than treatments with chemotherapy alone [79].
In summary, the strategy suggested might be clinically useful for those patients with cancer (e.g., HB)
that must be treated with chemotherapy (Table 3).
Recently, a case report has been published on a patient with lung cancer that was treated with
a combination therapy of aprepitant (1140 mg/day) and radiotherapy [80]. The patient was treated for
45 days and, six months after treatment, the tumor mass had disappeared [80]. Three years after the
treatment, the patient died due to causes not related to cancer [80]. More studies must be performed
to test combination therapy strategies. In addition, it is important to test the antitumor action of
aprepitant when administered alone (it has been suggested 25 mg/kg/day, for a long period of time
according to the response of the treatment) (Table 3) [81].
5. Safety Profile and Side-Effects of NK-1R Antagonists
Contrary to cytostatics, NK-1R antagonists at antiemetic doses do not produce serious side-effects,
although headaches, hiccupping, vertigo and drowsiness have been reported after administration of
these antagonists [82,83]. In patients with moderate to severe depression the safety of aprepitant was
reported: A dose of 300 mg/day was tolerated very well while no statistically significant difference in
the frequency of adverse events was observed as compared to the placebo [84]. The safety of aprepitant
against human fibroblasts has also been demonstrated: The IC50 for tumor cells (HB HepT1, HuH6,
and HepG2 cell lines were 28.5 µM, 31.1 µM and 33.18 µM, respectively) was lower than that for
fibroblasts (57.5 µM) [6]. In addition, the safety of aprepitant against lymphocytes has been recently
reported (IC50 176.2 µM) [85].
As mentioned above, a patient with lung cancer was treated for 45 days with aprepitant
(1140 mg/day) [80]. No side-effects were observed [80]. In this case report, the safety of aprepitant was
demonstrated since no biochemical analytical alteration was observed and the patient showed very
good general health, including weight gain [80]. This means that aprepitant is safe at the high dose
necessary for the HB treatment (25 mg/kg/day) [81].
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6. Conclusions
According to the data reported in previous sections, Table 3 shows the key-points in future HB
research. Altogether, data show that NK-1R is a new therapeutic target for the treatment of HB because
NK-1R antagonists (e.g., aprepitant) exert an antitumor effect (antiproliferative, apoptosis, tumor
volume is decreased) against HB cells (they overexpress the NK-1R (truncated form) and the receptor
must be used as a tumor marker). In addition, NK-1R antagonists decreased the angiogenic activity in
HB. This means that NK-1R antagonists exert a dual antitumor action in HB: Antiproliferative and
antiangiogenic, and that the SP/NK-1R system plays an important role in the tumor microenvironment.
In HB patients, the NK-1R may serve as a therapeutic target, independent of the clinical stage.
The tr-NK-1R isoform is expressed essentially among the different subsets of HB and it seems that
this isoform is associated with cancer rather than the full-length isoform. It seems that HB cells have
no possibility of becoming resistant to NK-1R antagonists since in HB cells the tr-NK-1R isoform
is continuously up-regulated (the truncated isoform could be responsible for a constitutive growth
stimulus) and, for this reason, the antitumor effect of the NK-1R antagonists is linked to the differential
expression of the NK-1R (truncated and full isoforms) in cancer cells. In combination therapy, NK-1R
antagonists (show no severe side-effects) and cytostatics produce an antitumor synergistic effect against
the HB cells (this is important in order to decrease the concentration of cytostatics in clinical practice),
decrease the toxicity of chemotherapeutics and increase the sensitivity of the HB cells to cytostatics.
Since aprepitant targets two crucial pathways involved in tumorigenesis (PI3K/Akt/mTOR and Wnt),
NK-1R antagonists could more easily block escape mechanisms in the HB cells and decrease HB
relapse/resistance. In summary, NK-1R is a new marker and target for the treatment of HB and NK-1R
antagonists exert an antitumor/antiangiogenic action against HB.
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